Skip to main content
    E

    enGene Therapeutics Inc. (ENGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.89
    -0.52 (-21.58%)

    Market Cap: $161.51M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    enGene Therapeutics Inc. (ENGN) Financials: Revenue, Profit and Cash Flow

    Updated Sep 8, 2026. Financial statements from company filings, amounts in US dollars.

    enGene Therapeutics reported revenue of $0 for the fiscal year ended Oct 31, 2025. That year, net income was -$117.30M, operating cash flow was -$99.24M and free cash flow was -$100.72M. The quarter ended Jul 31, 2026 had revenue of $0 and net income of -$32.50M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Oct 2025, with an operating loss of $123.17M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Oct 2025$0N/AN/AN/AN/A
    Oct 2024$0N/AN/AN/AN/A
    Oct 2023$0N/AN/AN/AN/A
    Oct 2022$0N/AN/AN/AN/A
    Oct 2021$0N/AN/AN/AN/A
    Oct 2020$0N/AN/AN/AN/A
    Annual, fiscal years ended Oct 2020 to Oct 2025

    Income Statement

    In the fiscal year ended Oct 2025, the net loss widened from the year before. In the quarter ended Jul 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemOct 2025Oct 2024Oct 2023Oct 2022Oct 2021Oct 2020
    Research and development$94.48M$38.31M$16.46M$15.47M$12.46M$10.61M
    Operating income-$123.17M-$62.30M-$26.06M-$19.43M-$15.87M-$13.85M
    Net income-$117.30M-$55.14M-$99.92M-$24.46M-$23.44M-$15.07M
    EBITDAN/A-$62.21MN/AN/AN/A-$12.90M
    Fiscal years ended Oct 2020 to Oct 2025

    Quarterly

    Line itemJul 2026Apr 2026Jan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024Jul 2024Apr 2024Jan 2024Oct 2023
    Revenue$0$0$0$0$0$0$0$480.00K$0$0$0$0
    Gross profit$0$0$0-$171.00K$0$0$0$240.00K$0$0$0N/A
    Operating income-$34.01M-$31.97M-$31.18M-$39.48M-$29.95M-$27.12M-$26.61M-$17.45M-$16.76M-$17.31M-$10.77M-$10.44M
    Net income-$32.50M-$30.23M-$29.75M-$37.88M-$28.99M-$25.82M-$24.62M-$15.30M-$14.15M-$14.98M-$10.71M-$82.50M
    Last 12 quarters

    Balance Sheet

    As of Oct 2025, cash and equivalents exceeded total debt of $23.33M by $26.83M.

    Annual

    Line itemOct 2025Oct 2024Oct 2023Oct 2022Oct 2021Oct 2020
    Total assets$221.47M$311.17M$86.96M$132.04M$131.45MN/A
    Current assets$201.39M$247.36M$85.44M$511.80K$1.57MN/A
    Cash and equivalents$50.15M$173.00M$81.52M$314.15K$1.07MN/A
    Total liabilities$53.76M$38.56M$14.47M$4.62M$4.05MN/A
    Short-term debt$8.00M$699.00K$562.00K$1.26M$1.05MN/A
    Long-term debt$15.32M$22.47M$9.22M$30.84M$3.05MN/A
    Shareholder equity$167.71M$272.61M$72.49M$127.42M$127.39MN/A
    Fiscal years ended Oct 2020 to Oct 2025

    Quarterly

    Line itemJul 2026Apr 2026Jan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024Jul 2024Apr 2024Jan 2024Oct 2023
    Total assets$288.32M$307.52M$337.11M$221.47M$245.55M$266.65M$285.93M$311.17M$266.88M$273.53M$93.42M$86.96M
    Total liabilities$58.03M$52.36M$55.57M$53.76M$44.88M$39.36M$35.98M$38.56M$36.55M$30.56M$31.04M$14.47M
    Cash and equivalents$41.02M$29.83M$36.61M$50.15M$32.62M$57.55M$62.35M$173.00M$257.68M$264.81M$85.65M$81.52M
    Shareholder equity$230.29M$255.17M$281.55M$167.71M$200.67M$227.29M$249.95M$272.61M$230.33M$242.97M$62.38M$72.49M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Oct 2025.

    Annual

    Line itemOct 2025Oct 2024Oct 2023Oct 2022Oct 2021Oct 2020
    Operating cash flow-$99.24M-$48.28M-$24.74M-$17.59M-$15.98M-$13.06M
    Capital expenditures$1.49M$925.00K$318.00K$153.00K$248.00K$192.00K
    Free cash flow-$100.72M-$49.21M-$25.06M-$17.75M-$16.23M-$13.25M
    Investing cash flow-$25.14M-$125.95M-$318.00K-$153.00K-$247.00K-$192.00K
    Financing cash flow$1.52M$265.72M$86.15M$27.97M$22.52M$12.85M
    Fiscal years ended Oct 2020 to Oct 2025

    Quarterly

    Line itemJul 2026Apr 2026Jan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024Jul 2024Apr 2024Jan 2024Oct 2023
    Operating cash flow-$18.95M-$30.50M-$28.90M-$24.96M-$25.63M-$22.95M-$25.70M-$19.57M-$7.18M-$14.16M-$7.37M-$6.78M
    Capital expendituresN/A$98.00K$153.00K$437.00K$704.00K$45.00K$299.00K$238.00K$2.00K$179.00K$506.00K$138.00K
    Free cash flowN/A-$30.60M-$29.06M-$25.40M-$26.34M-$22.99M-$26.00M-$19.81M-$7.18M-$14.34M-$7.88M-$6.91M
    Last 12 quarters

    Frequently Asked Questions About ENGN

    What is enGene Therapeutics' annual revenue?

    enGene Therapeutics reported revenue of $0 for the fiscal year ended Oct 31, 2025.

    Is enGene Therapeutics profitable?

    No. enGene Therapeutics reported net income of -$117.30M for the fiscal year ended Oct 31, 2025.

    How much free cash flow does ENGN generate?

    For the fiscal year ended Oct 31, 2025, operating cash flow of -$99.24M minus capital expenditures of $1.49M produced free cash flow of -$100.72M.

    How much debt does enGene Therapeutics have?

    The balance sheet dated Oct 31, 2025 reported long-term debt of $15.32M, short-term debt of $8.00M and cash and equivalents of $50.15M.